The United States of America, as Represented by the Secretary, Department of Health and Human Services

University of Kansas

Forschungsverbund Berlin E.v.

Johns Hopkins University

Northwestern University

The University of North Carolina at Chapel Hill

Florida International University

Other

University System of Maryland

Icahn School of Medicine at Mount Sinai

Pontificia Universidad Catòlica De Chile

The United States of America, as Represented by Th

Pontifica Universidad Catoclica De Chile

Noel Terrence Southall

Juan Jose Marugan

Wei Ping Zheng

Marc Ferrer

Xin Hu

Samarjit Patnaik

Steven Titus

Kevin Frankowski

Wenwei Huang

Craig J Thomas

Frank John Schoenen

James Inglese

Wendy Westbroek

Ehud Goldin

Jingbo Xiao

Marvin C Gershengorn

Susanne Neumann

Bruce M Raaka

Gerd Krause

Gunnar Kleinau

Ellen Sidransky

David Robert Sibley

Marc Ferrer-Alegre

R Benjamin Free

Christopher P Austin

Catherine Chen

Warren S Weiner

Sui Huang

John Thomas Norton

Ravit Boger

Irina Agoulnik

Joseph Perry Steiner

Jeffrey Aubé

Ke Liu

Steven Andrew Rogers

Yiannis A Ioannou

Chen Wang

Patricia Dranchak

Prashi Jain

Omid Motabar

Alexander Agoulnik

Daniel C Talley

Christopher R Dextras

Andres E Dulcey

Rommy M Von Bernhardi

Alejandra Alvarez

Amy Elizabeth Moritz

Silvana Zanlungo

Andres Dulcey Garcia

Wei Zheng

Kelin Li

Elma Aflaki

Liudmila Kulakova

Osnat Herzberg

Mercedes Taylor

Raul Rolando Calvo

Seameen Dehdasthi

Fannie Chen

Tsanyang Liang

Zongyi Hu

Shanshan He

Udo Rudloff

Pu Liu

Lea Cunningham

Andrey Galkin

Chrisopher P Austin

Kevin J Frankowski

M Ehud Goldin

Wendy Westbrook

Jeffrey AubÉ

Kathryn D Luderman

Jennie L Conroy

John C Braisted

Serguei Kozlov

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as 'c-Abl'). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof

Selective D3 dopamine receptor agonists and methods of their use

C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

Selective Ddopamine receptor agonists and methods of their use

Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R-Rand X are described in the application.

Substituted pyrazolopyrimidines as glucocerebrosidase activators

The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R, R, R, and Rare as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal. 

Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1: 

Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders

Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers. 

Heterocyclic compounds and methods of use thereof

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R, and Rare as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1. 

Modulators of the relaxin receptor 1

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of &#x3b4; tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of &#x3b4; tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of &#x3b4; tocopherol in combination with cyclodextrin to a patient in need thereof.

Use of delta tocopherol for the treatment of lysosomal storage disorders

The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine Dreceptor. The variables R-R, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia. 

11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists

Growing community of inventors

Potomac, MD, United States of America

Noel Terrence Southall